AU2337200A - A method for introducing substances into cells, and use of said method - Google Patents

Description

WO_00/42202 PCT/SEOO/00073 A METHOD FOR INTRODUCING SUBSTANCES INTO CELLS, AND USE OF SAID METHOD Field of the invention The present invention relates to in vitro and in vivo methods for introducing substances into a mammalian stem cell and/or progenitor cells, as well as to use of 5 such methods. Background of the invention For several years it has been clear that cellular mechanisms exist that allow cells to internalize nucleic 10 acids. A new approach for chemotherapy has been developed based on the fact that addition of defined oligonucleo tides (antisense inhibitors) to cells in tissue culture has been shown to block specific gene expression. Previous studies have established that short single 15 stranded DNAs are rapidly internalized by a variety of cultured cells (Bennett, R. M., Gabor, G. T. and Merritt, M. M., J. Clin. Invest. 76, 2182-2190 (1985); Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S. and Neckers, L. M., 20 Proc. Natl. Acad. Sci. USA 86, 3474-3478 (1989); Yakubov, L. A., Deeva, E. A., Zarytova, V. F., Ivanova, E. M., Ryte, A. S., Yurchenko, L. V., and Vlassov, V. V., Poc. Natl. Acad. Sci. USA 86, 6454-6458 (1989); Iversen, P. L., Zhu, S., Meyer, A., and Zon, G., Antisense Res. 25 Dev. 2, 211-222 (1992); Wu-Pong, S., Weiss, T. L., and Hunt, C. A. Pharmacol. Res. 9, 1010-1017 (1992); Chan, T. M., Framton, G and Cameron, J. S., Clin. Exp. Immunol. 91, 110-114 (1993)). There are reports of DNA receptor structures that mediate uptake and destruction of DNA in 30 human leucocytes ((Bennett, R. M., Gabor, G. T. and Mer ritt, M. M. J. Clin. Invest. 76, 2182-2190 (1985)). However, naked DNA, RNA and oligonucleotides are in general unable to cross cellular membranes in vivo (Bo- WO 00/42202 PCT/SEOO/00073 2 ado, R. J., Tsukamoto, H. and Pardridge, W. M. J. Pharm. Sci. 87, 1308-1315 (1998). Therefore, several strategies based on the binding of DNA to soluble carriers, receptor structures or conjugates (e.g. DNA binding proteins, con 5 jugates of poly-L-lysine and an integrin receptor ligand) mediating the interaction with a transmembraneous trans port system (see e.g. WO 96/15811; WO 94/25608; Kato, Y. and Sugiyama, Y. Crit. Rev. Ther. Drug Carrier syst. 14, 287-331 (1997)). 10 In general, replacement of neurons following degen eration or damage is not a characteristic of the mammal ian brain. Neuronal loss is thus considered permanent. Prolonged postnatal neurogenesis has been described in the granule cell layer of the hippocampal formation (Alt 15 man, J. and Das, G. D., J. Comp. Neurol. 124: 319-335 (1965); Altman, J. and Das, G. D., Nature 214: 1098-1101 (1967); Caviness, V. S. jr., J. Comp Neurol. 151: 113-120 (1973); Gueneau, G., Privat, A., Drouet, J., and Court, L., Dev. Neurosci. 5, 345-358(1982); Eckenhoff, M. F. and 20 Rakic, P., J. Neurosci. 8: 2729-2747(1988)). Cell genesis and neurogenesis have recently been shown to persist well into adulthood in man (Eriksson, P. S., Perfilieva, E., Bj6rk-Eriksson, T., Alborn, A., Nordborg, C., Peterson, D. A., Gage, F. H., Nature Med. 4:1313-1317 (1998). 25 Newborn neurons in the granule cell layer express markers of differentiated neurons and have morphological characteristics corresponding to differentiated granulae cells (Kaplan, M. S. and Bell, D. H., J. Neurosci. 4: 1429-1441 (1984); Cameron, H. A., Woolley, C. S., McEwen, 30 B. S., and Gould, E., Neuroscience 56: 337-344 (1993); Cameron, H. A., Woolley, C. S., and Gould, E., Brain Res. 611: 342-346 (1993)). Furthermore, they establish axonal processes into the mossy fiber pathway and form synaptic connections with their targets in hippocampus CA3 (Seki, 35 T. and Arai, Y., J. Neurosci. 13: 2351-2358 (1993); Stan field, B. B., and Trice, J. E., Exp. Brain Res. 72: 399 406 (1988)). The hippocampus is associated with spatial WO 00/42202 PCT/SEOO/00073 3 learning and memory (McNamara, R. K., and Skelton, R. W., Brain Res. Rev. 18: 33-49 (1993)). The proliferation of progenitor cells can be influenced by the administration of N-methyl-D-aspartate (NMDA) receptor antagonists or by 5 the removal of the adrenal glands (Cameron, H. A., and Gould, E., Neuroscience 61: 203-209 (1994); Cameron, H. A., Tanapat, P., and Gould, E., Neuroscience 82: 349 354 (1998)). Plasticity is reduced with increasing age, and recent studies have demonstrated that proliferation 10 of progenitor cells also is decreased but not completely abolished with age (Kuhn, H., Dickinson-Anson, H., and Gage, F. H., J. Neurosci. 16: 2027-2033 (1996)). Stem cells, isolated through a time consuming and laborious tissue culture procedure, from the adult rodent brain has 15 recently been transplanted into the brain of adult ani mals where they differentiate into cells with neuronal characteristics (Suhonen, J. 0., Peterson, D. A., Ray, J., and Gage, F. H., Nature 383:624-627 (1996)). There are so far no known stem cell markers that are usable for 20 rapid isolation of stem cells or progenitor cells from the adult central nervous system. This fact inhibits the therapeutic use of stem cells in humans. So far the de tection of stem cells rely on indirect detection method using modified nucleotides that incorporates in to the 25 genome in dividing cells during the S-phase of the cell cycle. Thereafter, the phenotype of the progeny can be detected using immunohistochemical methods. The limita tion with this way of identifying progenitor progeny is that these cells no longer possess the stem cell or pro 30 genitor cell properties meaning that these cells lack the ability to self renew and to give rise to neurons, as troglia, or oligodendrocytes. Alternative strategies to isolate stemcells from rodents, based on either unselec tive dye staining, immunosorting with antibodies against 35 the protein nestin expressed by all cells surrounding the ventricles, or unselective infection with viruses carry ing the gene for a selectable marker, was recently pub- WO_00/42202 PCT/SEOO/00073 4 lished (Johansson, C. B., Momma, S., Clarke, D. L., Ris ling, M., Lendahl, U., Frisen, J., Cell 96: 25-34 (1999)). Neither of these methods is highly efficient and thus unsuitable for rapid isolation of stemcells from 5 small human tissue samples. Therefore, it is of impor tance to identify a usable marker or property allowing for rapid isolation of stem or progenitor cells for therapeutic purposes e.g. autologous neural transplanta tion. 10 Summary of the invention Due to the fact that mammalian progenitor cells and stem cells from the adult CNS lack specific marker mole cules it has up to now been virtually impossible to per 15 form rapid detection and isolation of those cells. During the work leading to the present invention it was found that progenitor cells and stem cells from the adult brain possess a highly efficient mechanism for uptake of nu cleic acids, such as DNA. It was also found that it is 20 possible to use said transport system in order to mark or tag progenitor cells and stem cells via administration of e.g. double stranded DNA either in linear form or in cir cular form (plasmids) which is taken up by the progenitor cells or the stem cells via direct interaction between 25 the DNA and the cells, without the use of facilitating drugs, carriers, soluble receptors or chemicals or any special devices. The DNA is not immediately degraded. In stead, if the plasmid DNA contains the necessary compo nents for expression, the aforementioned cells can be de 30 tected by the expression of plasmid cDNAs. If the DNA/plasmid, containing suitable elements for expression, cDNA and promotor, is incubated in the presence of pro genitor cells or stem cells, said DNA is taken up effi ciently and the protein corresponding to the cDNA is ex 35 pressed by the progenitor cells or stem cells. The invention is based on the use of this nucleic acid transport system in progenitor cells and stem cells WO00/42202 PCT/SEOO/00073 5 for different purposes. According to the present inven tion, it is possible to transfer DNA without the help or aid of e.g. viral vectors. The invention provides new methods to isolate progenitor cells and stem cells in 5 vivo and in vitro. This isolation may be based on the ex pression from plasmid containing cDNA of a protein that enables selective identification and isolation based on immunoreactivity, or on the expression by DNA of a pro tein that enables selective identification and isolation 10 based on the expression of fluorescent proteins, includ ing FACS sorting. The invention also provides new methods to transport different substances with e.g. pharmaceuti cal effects into progenitor cells and/or stem cells. The object of the invention is thus a method for in 15 troducing a substance comprising a nucleic acid into a mammalian neural stem cell or progenitor cell, character ized in that said nucleic acid directly interacts with the cell membrane of said cell or a component within said cell membrane in vitro whereby the substance comprising 20 said nucleic acid is taken up by the cell via the inher ent transport mechanism of the cell. Said method may be performed both in vitro and in vivo. The method is particularly suitable for isolation of progenitor cells or stem cells from the adult brain, for 25 gene therapy, for cell sorting and for diagnostic proce dures. The characterizing features of the invention will be evident from the following description and the appended claims. 30 There are several advantages with the present inven tion compared with known strategies based on the binding of DNA to a soluble carrier, a receptor structure or a conjugate (such as a DNA binding protein, a conjugate of poly-L-lysine and an integrin receptor ligand) mediating 35 the interaction with a transmembraneous transport system. One important advantage is that the invention does not rely on the binding of DNA to any soluble receptors or WO00/42202 PCT/SE00/00073 6 carriers. Another important advantage is that it allows for the selective labeling of cells, due to the fact that only cells with the above described inherent transport mechanism are transfected. 5 Detailed description of the invention The transport mechanism upon which the present in vention is based and which is found in mammalian stem cells and progenitor cells from the brain, including hu 10 man stem cells and progenitor cells from the brain, can be utilized in order to transport single or double stranded DNA or RNA into a cell and subsequently allow for the DNA or RNA to remain intact and undegraded in the cell. Cells in which this transport mechanism is found 15 are especially adult derived neural stem cells and pro genitor cells. By utilizing this transport it is thus possible to insert nucleic acids into said cells. These nucleic acids may either be used for their 20 ability to make it possible to identify and thus isolate progenitor cells and stem cells from other cells, or for their pharmaceutical effects. As stated above, the present invention relates to a method for introducing a substance comprising a nucleic 25 acid into a mammalian neural stem cell or progenitor cell, characterized in that said substance is brought into contact with said cell, whereby it is taken up by the cell via the inherent transport mechanism of the cell. The method may be used both in vitro and in vivo. 30 The cells used in the method according to the invention are preferably derived from an adult. The substance to be introduced into a cell according to the method is or comprises e.g. a single or double stranded, linear or circular DNA, or a single or double 35 stranded RNA. The substance may also be a fusion molecule comprising a nucleic acid part and a protein part, or an expression vector containing a specific cDNA. The expres- WO_00/42202 PCT/SEOO/00073 7 sion "expression vector" used herein relates to all vec tors or plasmids consisting of a double stranded DNA structure comprising cDNA for a specific peptide or pro tein. Once this expression vector is taken up by the stem 5 cells or progenitor cells it will lead to the synthesis of said peptide or protein. When the substance is an expression vector it is preferably, according to one embodiment of the invention further commented on below, that the cDNA gives rise to a 10 peptide or protein that activate proliferation and/or differentiation and/or lineage determination of said cells. As stated above, the method according to the inven tion may be performed both in vitro, e.g. in a tissue or 15 cell culture, and in vivo. When the method is performed in vivo, the cells into which the substance is trans ported are preferably cells in the central nervous sys tem. The methods according to the invention may be used 20 for several different purposes, both diagnostic and therapeutic. When the method is performed in vitro, it is espe cially suitable for the identification of progenitor cells and stem cells. When the methods according to the 25 invention are used for the purpose of identification it is preferable that the substance that is to be introduced into said cells gives rise to a detectable signal or to a peptide or protein that enables selective identification of stem cells and progenitor cells. Said peptide or pro 30 tein may then in its turn give rise to a detectable sig nal, as the case is for e.g. a fluorescent protein, or a marker protein. Examples of suitable markers for stem cells or progenitor cells are protein components of the transport system, such as receptors and carriers. The de 35 tectable signal may also be obtained by the use of tagged substances, such as a radioactively tagged nucleic acid.

WO 00/42202 PCT/SEOO/00073 8 It is especially interesting to be able to identify, and thereafter isolate, progenitor cells and stem cells in samples constituted of e.g. different structures of brain tissue taken out of a patient or cells cultured 5 from a patient. Once the stem cells or progenitor cells have been identified, they can be isolated from the other types of cells in the sample by any appropriate method known to man skilled in the art. The isolated cells can then for 10 example be used in different tests, for diagnostic pur poses or be propagated and transplanted to a patient. The in vivo method can be used in order to identify, and subsequently isolate, cells in vivo, in a way similar to the in vitro method described above. When the method 15 is performed in vivo, it is possible to identify, and thus isolate, stem cells and progenitor cells in differ ent structures of the intact brain It is also possible to propagate stem cells and pro genitor cells with the methods according to the inven 20 tion. This propagation can be performed both in vitro and in vivo. The cells, which optionally first may have been identified and isolated with the methods according to the invention, are then brought in contact with a substance that comprises or gives rise to peptide or protein that, 25 once it is taken up by the cells, activate proliferation and/or differentiation and/or lineage determination of said cells. It is also possible to use both the in vitro and the in vivo methods according to the invention for gene ther 30 apy. The substance that is brought into contact with the cells, and subsequently is transported into the cells, may then be a pharmaceutically active substance. It may also give rise to a pharmaceutically active substance once it is taken up by the cells. The substance may then 35 e.g. be an expression vector comprising cDNA encoding the pharmaceutically active substance. The pharmaceutically active substance produced by the cDNA once it is taken up WO00/42202 PCT/SEOO/00073 9 by the cell may be a peptide or protein that will get transported out of the progenitor cell or stem cell to affect surrounding tissue or cells. Examples of such a peptide or protein are trophic factors, or other proteins 5 exerting a desired action on neighboring cells and tis sues. The peptide or protein produced by the cDNA may also be a substance that will either activate or inacti vate proliferation, differentiation or specific lineage determination of the progenitor cells or stem cells ei 10 ther in order to be able to more easily isolate progeni tors or stem cells or in order to induce the genesis of new neurons, astrocytes or oligodendrocytes from progeni tors or stem cells in the brain or within progenitors or stem cells in a tissue culture for concomitant use for 15 transplantation of said cells to patients. It is also possible to use a substance constituted of a fusion mole cule between a nucleic acid, that enables the transport into the cells, and a pharmaceutically active protein. When the gene therapy is performed in vivo, it can 20 be used for treatment of neurological insult, disease, deficit or condition in a patient. The term "treatment" used herein relates to both treatment in order to cure or alleviate a disease or a condition, and to treatment in order to prevent the development of a disease or a condi 25 tion. The treatment may either be performed in an acute or in a chronic way. The term "patient", as it is used herein, relates to any human or non-human mammal in need of treatment according to the invention. It is possible to produce medicinal products for 30 treatment of conditions due to disturbances of the normal function of stem cells or progenitor cells by attaching a pharmaceutically active compound to a nucleic acid. The nucleic acid will, when it is brought into contact with a stem cell or progenitor cell, be taken up into the cell 35 by the inherent transport mechanism of the cell, and since the pharmaceutically active compound is attached to the nucleic acid it too will be transported in to the WO 00/42202 PCT/SEOO/00073 10 cell. Such medicinal products may also comprise other substances, such as an inert vehicle, or pharmaceutical acceptable adjuvants, carriers, preservatives etc., which are well known to persons skilled in the art. It is pref 5 erable that such medicinal products are administered to a patient by infusion into the cerebral ventricles through a surgically inserted canula or via a syringe inserted between lumbar vertebras and into the spinal fluid. The methods according to the invention can also be 10 used in order to test or screen a protein or a detectable signal. In a screening or test application the invention is used in with stemcells that take up DNA including cDNA coding for a protein of interest that are subject to screening or testing. Examples of proteins are receptors 15 that can be used for screening new receptor agonists. The transport and uptake of and subsequent expression from plasmids in cells according to the invention can be used in detector devices and screening devices where expres sion of specific proteins like receptors or enzymes are 20 desired. The advantage of the present invention compared with conventional transfection techniques in which drugs or compounds that facilitate DNA uptake are necessary for efficient uptake and expression, is the high efficiency and lack of need for drugs, compounds or chemicals to fa 25 cilitate uptake and subsequent expression of proteins. The invention will now be further explained in the following example. This example is only intended to il lustrate the invention and should in no way be considered to limit the scope of the invention. 30 Brief description of the drawing In the example below, reference will be made to the accompanying figure, wherein: Figure 1A is a fluorescence photomicrograph showing the 35 result of incubation of progenitor cells in me dium with 50 tg/ml of a plasmid containing the cDNA for GFP; WO00/42202 PCT/SEOO/00073 11 Figure 1B a lightmicroscopic image showing the same re sult as figure 1A; Figure 1C is a fluorescence photomicrograph showing the result of incubation of progenitor cells in me 5 dium with 50 pg/ml of another plasmid not con taining the GFP gene; and Figure 1D a lightmicroscopic image showing the same re sult as figure 1B. 10 Example Expression by porogenitor cells from mature rat brain of a fluorescent marker The expression of green fluorescent protein (GFP) was examined in progenitor cells isolated from the adult 15 hippocampus. Progenitor cells (Palmer, T. D., Ray, J. and Gage, F. H. (1995) Mol. Cell. Neurosci. 6: 474-486.) and cos-7 cells were cultured according to standard proce dures and plated onto 1-inch circular coverslips coated with poly-D-ornithine and lamilin. The cells were incu 20 bated with plasmids containing the cDNA for GFP, and plasmids deficient of the GFP gene, respectively, in a humid atmosphere at 37 0 C with 5% CO 2 and 95% air for 10 minutes. The cells were cultured for 48 h, following DNA exposition. 25 Thereafter the expression of the fluorescent protein was detected using an inverted Leica DMIRB microscope equipped for fluorescence microscopy. The cells were viewed in the microscope using excitation of GFP at 488 nm using an Ar-ion laser (Spectra Physics model 2025-05, 30 Sunnyvale, CA). The laser light was sent through a 488 line interference filter followed by a spinning disk to break the coherence and scatter the laser light. The la ser was collected by a lens and sent through a fluores cein filter cube (Leica 1-3) into the objective to excite 35 the fluorophores. The resulting fluorescence was col lected by the same objective and the image was detected by a 3-chip color CCD-camera (Panasonic) and recorded at WO 00/42202 PCT/SE0O/00073 12 25 Hz frame collection rate by a Super VHS (Panasonic SVHS AG-5700). The CCD images were digitized from tape and processed for presentation. When progenitor cells were incubated in medium with 5 50 tg/ml of a plasmid containing the cDNA for GFP for 10 minutes without addition of chemicals that facilitate up take or transport of DNA, and thereafter grown for 48h before detection, they were highly fluorescent. Figure 1A is a fluorescence photomicrograph showing this result, 10 and Figure 1B shows the respective lightmicroscopic im age. In contrast, when progenitor cells from adult rat brain were incubated with other plasmids not containing the GFP gene, no fluorescence was observed. Figure 1C and 15 1D show the respective images when GFP deficient plasmid DNA were used. Also, when progenitor cells were incubated with plasmid containing the gene expressing b-galactosidase 50 [tg/ml, without addition of chemicals that facilitate 20 uptake or transport of DNA, and thereafter grown for 48 h before detection, cells expressed b-galactosidase activ ity. It was also found that kidney-derived Cos-7 cells that were incubated in medium with 50 pig/ml of a plasmid 25 containing the cDNA for GFP for 10 minutes without addi tion of chemicals that facilitate uptake or transport of DNA, and thereafter grown for 48h before detection, lack expression of green fluorescent protein (GFP). Detection and experimental procedures for this experiment was iden 30 tical to that for progenitor cells exposed to plasmid containing the cDNA for GFP. Also, when cos-7 cells were incubated with plasmid containing the gene expressing b-galactosidase, without addition of chemicals that facilitate uptake or transport 35 of DNA, and thereafter grown for 48 h before detection, they displayed a lack of expression of b-galactosidase activity.

WO 00/42202 PCT/SEOO/00073 13 It is clear from the above experiments that progeni tor cells from adult rat brain has a capacity to in vitro transport double-stranded DNA plasmids to their interi ors, and to synthesize the proteins that the DNA sequence 5 codes for.

Claims (45)

1. A method for introducing a substance comprising a nucleic acid into a mammalian neural stem cell or pro 5 genitor cell, characterized in that said nucleic acid directly interacts with the cell membrane of said cell or a component within said cell membrane in vitro whereby the substance comprising said nucleic acid is taken up by the cell via the inherent transport mechanism of the 10 cell.

2. A method according to claim 1, wherein said cell is derived from an adult.

3. A method according to claim 2, wherein said method is performed in a humid atmosphere at 37 0 C. 15

4. A method according to any one of the claims 1-3, wherein said substance is or comprises a single or double stranded, linear or circular DNA.

5. A method according to any one of the claims 1-3, wherein said substance is or comprises a single or double 20 stranded RNA.

6. A method according to any one of the claims 1-3, wherein said substance is a fusion molecule comprising a nucleic acid part and a protein part.

7. A method according to any one of the claims 1-3, 25 wherein said substance is an expression vector containing a specific cDNA.

8. A method according to claim 7, wherein said cDNA gives rise to a peptide or protein that activate prolif eration and/or differentiation and/or lineage determina 30 tion of said cells.

9. A method according to any one of the claims 1-6, wherein said substance gives rise to a detectable signal.

10. A method according to claim 7, wherein said cDNA gives rise to a peptide or protein that enables selective 35 identification of stem cells and/or progenitor cells.

11. A method according to claim 10, wherein said peptide or protein gives rise to a detectable signal. WO 00/42202 PCT/SEOO/00073 15

12. A method according to claim 11, wherein said protein is a fluorescent protein.

13. A method according to claim 11 or 12, wherein said detectable signal is due to a radioactively tagged 5 nucleic acid.

14. A method according to any one of the claims 1 13, wherein said cell is a cell in a tissue or cell cul ture.

15. Use of a method according to any one of the 10 claims 1-14, for identification of progenitor cells and/or stem cells.

16. Use according to claim 15, wherein said cells after identification is isolated from surrounding cells of other types. 15

17. Use of a method according to any one of the claims 1-14, for gene therapy.

18. Use of a method according to claim 6 and 17, wherein said protein part consists of a pharmaceutically active protein. 20

19. Use of a method according to claim 8, for propa gation of neural cells.

20. Use according to claim 18, wherein said propa gated neural cells are suitable for transplantation to patients. 25

21. Use of a method according to any one of the claims 1-14, for detection of a medicinal product com prising cDNA containing expression plasmids.

22. Use of a method according to any one of the claims 1-14, for diagnostic purposes. 30

23. Use of a method according to any one of the claims 8-13, wherein said protein or detectable signal allows for testing or screening of aforementioned protein or signal.

24. A method for introducing a substance comprising 35 a nucleic acid into a mammalian neural stem cell or pro genitor cell, characterized in that said nucleic acid directly interacts with the cell membrane of said cell or WO 00/42202 PCT/SEO0/00073 16 a component within said cell membrane in vivo, whereby the substance comprising said nucleic acid is taken up by the cell via the inherent transport mechanism of the cell. 5

25. A method according to claim 24, wherein said cell is derived from an adult.

26. A method according to claim 24, wherein said substance is or comprises a single or double stranded, linear or circular DNA. 10

27. A method according to claim 24, wherein said substance is or comprises a single or double stranded RNA.

28. A method according to claim 24, wherein said substance is a fusion molecule comprising a nucleic acid 15 part and a protein part.

29. A method according to claim 24, wherein said substance is an expression vector containing a specific cDNA.

30. A method according to claim 29, wherein said 20 cDNA gives rise to a peptide or protein that activate proliferation and/or differentiation and/or lineage de termination of said cells.

31. A method according to claim 24, wherein said substance gives rise to a detectable signal. 25

32. A method according to claim 29, wherein said cDNA gives rise to a peptide or protein that enables se lective identification of stem cells and/or progenitor cells.

33. A method according to claim 32, wherein said 30 peptide or protein gives rise to a detectable signal.

34. A method according to claim 33, wherein said protein is a fluorescent protein.

35. A method according to claim 33, wherein said de tectable signal is due to a radioactively tagged nucleic 35 acid. WO 00/42202 PCT/SEOO/00073 17

36. A method according to any one of the claims 1 13, wherein said cell is a cell in the central nervous system of a patient.

37. Use of a method according to claim 24, for iden 5 tification of progenitor cells and/or stem cells.

38. Use according to claim 37, wherein said cells after identification is isolated from surrounding cells of other types.

39. Use of a method according to any one of the 10 claims 24-38 for gene therapy.

40. Use of a method according to claim 28, wherein said protein part consists of a pharmaceutically active protein.

41. Use of a method according to claim 30, for 15 propagation of neural cells.

42. Use of a method according to any one of the claims 24-36, for detection of a medicinal product com prising cDNA containing expression plasmids.

43. Use of a method according to any one of the 20 claims 24-36, for diagnostic purposes.

44. Use of a method according to any one of the claims 30-35, wherein said protein or detectable signal allows for testing or screening of aforementioned protein or signal. 25

45. Use of a method according to claim 24, for treatment of neurological insult, disease, deficit or condition.